BNTX: BioNTech SE
About
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Current Value
$117.251 Year Return
Current Value
$117.251 Year Return
Key Details
Market Cap
$28.10B
P/E Ratio
-55.79
1Y Stock Return
17.31%
1Y Revenue Growth
-52.11%
Dividend Yield
0.00%
Price to Book
1.3
Strategies that include BNTX
Stock's related to BNTX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MRNA | 47.89% | $17.03B | -44.58% | 0.00% |
| PFE | 42.74% | $146.32B | -11.82% | 6.51% |
| RDFN | 42.20% | $1.20B | +28.17% | 0.00% |
| WBD | 38.29% | $25.91B | -7.29% | 0.00% |
| BC | 37.58% | $5.27B | -4.14% | 2.10% |
| PII | 37.00% | $3.78B | -21.61% | 3.90% |
| MCFT | 36.84% | $353.22M | -0.19% | 0.00% |
| CVAC | 36.42% | $654.97M | -47.48% | 0.00% |
| HZO | 35.92% | $739.07M | -1.15% | 0.00% |
| U | 35.83% | $9.77B | -25.68% | 0.00% |
| ARCT | 35.65% | $504.91M | -22.30% | 0.00% |
| CRSP | 35.31% | $4.71B | -22.88% | 0.00% |
| MC | 35.25% | $5.35B | +48.10% | 3.14% |
| KBH | 35.00% | $6.10B | +51.97% | 1.14% |
| EXPI | 34.99% | $2.17B | +7.46% | 1.42% |
| BRC | 34.90% | $3.60B | +32.43% | 1.25% |
| RH | 34.80% | $7.01B | +30.66% | 0.00% |
| SHOO | 34.74% | $3.33B | +16.18% | 1.80% |
| OPEN | 34.33% | $1.52B | -37.54% | 0.00% |
| RLAY | 34.28% | $781.68M | -43.87% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NTNX | -15.69% | $17.72B | +48.69% | 0.00% |
| ADBE | -15.63% | $227.23B | -14.62% | 0.00% |
| STG | -12.62% | $32.56M | -29.30% | 0.00% |
| XGN | -10.48% | $73.90M | +131.49% | 0.00% |
| LITB | -9.72% | $33.46M | -74.29% | 0.00% |
| TCTM | -9.34% | $7.90M | -31.31% | 0.00% |
| SMWB | -7.60% | $1.04B | +151.02% | 0.00% |
| AZO | -7.59% | $53.75B | +19.35% | 0.00% |
| CYBR | -7.05% | $13.90B | +56.25% | 0.00% |
| CMG | -6.62% | $82.49B | +36.40% | 0.00% |
| SAVA | -6.57% | $165.74M | -84.44% | 0.00% |
| PPC | -6.10% | $12.19B | +96.11% | 0.00% |
| PEN | -6.07% | $9.40B | +7.13% | 0.00% |
| CBOE | -5.78% | $22.18B | +16.57% | 1.10% |
| CNSL | -5.64% | $554.43M | +7.59% | 0.00% |
| BTCT | -5.31% | $60.65M | +335.42% | 0.00% |
| GAN | -5.25% | $82.94M | +21.33% | 0.00% |
| VHC | -4.58% | $18.98M | -30.75% | 0.00% |
| NEUE | -4.49% | $41.67M | -22.85% | 0.00% |
| CYD | -4.02% | $384.89M | +1.29% | 4.07% |
ETF's related to BNTX
News
Yahoo
We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other high growth healthcare stocks. Global Healthcare Spending Trends and Investment Opportunities During lean economic times, investing in healthcare stocks is […]
Yahoo
JPMorgan lowered the firm’s price target on BioNTech (BNTX) to $122 from $124 and keeps a Neutral rating on the shares. The firm updated estimates for the company and refreshed its script trend analysis for the COVID vaccines. While the start of the U.S. vaccination season was pulled forward compared to 2023, the overall the peak is lower based on COVID vaccine trends up to mid-November, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time
Yahoo
Evercore ISI upgraded BioNTech (BNTX) to Outperform from In Line with a price target of $125, up from $110. The firm says it has been “growing increasingly constructive for some time now.” The upgrade is combination of opportunism in the shares, valuation, and an increasingly compelling fundamental outlook around BioNTech’s “deep and staggered” oncology pipeline, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking
Yahoo
Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will revolutionize the treatment of multiple diseases. However, the analyst prefers BioNTech (BNTX) for exposure relative to Moderna. Moderna is quickly spending its COVID cash and will not meet 2028 breakeven guidance, despite recent downgrades, the analyst tells investors in a research note. Berenberg says the company is more vulnerable to commercial pressure due to i
Yahoo
Berenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize the treatment of multiple diseases. The analyst prefers BioNTech for exposure citing its “superior financial management and balance sheet, higher returns and oncology focus.” BioNTech’s shares trade below the value of its cash position and marketed COVID-19 business, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-t
Yahoo
We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other German stocks. In Germany, the economic growth is based on industry. According to Deutschland.de, Germany’s manufacturing industry contributed 26.6% to the country’s gross […]
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.